OPEN NOW: CASPS – A Phase II Trial of Cediranib in the Treatment of Patients with Alveolar Soft Part Sarcoma
Sponsored by: The Institute of Cancer Research / The Royal Marsden NHS Foundation Trust
Information provided by: The Institute of Cancer Research – Clinical Trials and Statistics Unit
ClinicalTrials.gov Identifier: NCT01337401
Cediranib (AZD2171) is a new, unlicensed drug that has been studied in the laboratory and clinic, and researchers think it could slow the spread of ASPS. CASPS is a small clinical trial investigating cediranib in the treatment of ASPS, which is currently open to recruitment in the UK, Australia and Spain. Further information on CASPS and a list of hospitals involved in the trial can be found at http://cancerhelp.cancerresearchuk.org/trials/a-trial-cediranib-alveolar-soft-part-sarcoma-casps.
Objective: The aim of this study is to see if cediranib (AZD2171) can help people with alveolar soft part sarcoma.
Eligibility: Individuals 16 years of age and older who have been diagnosed with alveolar soft part sarcoma. Please note that other eligibility criteria do apply – for further details please go to http://cancerhelp.cancerresearchuk.org/trials/a-trial-cediranib-alveolar-soft-part-sarcoma-casps.
Contact: Professor Ian Judson: email@example.com
Locations: United Kingdom, Australia, Spain
Yosef Landesman, Ph.D.
President & Cancer Research Director
Cure Alveolar Soft Part Sarcoma International (iCureASPS)